Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
It has become widely used due to its ability to help patients lose a significant percentage of body weight while also improving cardiovascular outcomes
Users report feeling more energy and motivation, leading to more active and social lives
In essence, its like a melting or dissolving of fat, achieved by triggering the bodys own chemical mechanisms
We dig into newly released Phase 2b data from Pfizers once-monthly GLP-1 candidate (formerly Metseras asset), what the results actually show, and how it stacks up in an increasingly crowded field that includes Novo Nordisk, Eli Lilly, and next-gen combination therapies
Drug name Last update: Jul 2026 Developer(s) Semaglutide OZEMPIC
